Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

Teru Hideshima, Constantine Mitsiades, Hiroshi Ikeda, Dharminder Chauhan, Noopur Raje, Gullu Gorgun, Hiromasa Hideshima, Nikhil C. Munshi, Paul G. Richardson, Daniel R. Carrasco, Kenneth C. Anderson

Blood (2010) 115 (18): 3772–3775.

https://doi.org/10.1182/blood-2010-02-270082

Published: 2010

Includes: Supplemental data

Journal Articles

Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.

Teru Hideshima, MD, PhD, Hiroshi Yasui, MD, PhD, Laurence Catley, MD, Noopur Raje, MD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Klaus Podar, MD, PhD, Constantine Mitsiades, MD, PhD, Yu-Tzu Tai, PhD, Sonia Vallet, MD, Tanyel Kizitepe, PhD, Enrique Ocio, MD, PhD, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, PhD, Hiromasa Hideshima, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3410.

https://doi.org/10.1182/blood.V108.11.3410.3410

Published: 2006

Journal Articles

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

Kenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, Noopur Raje, Shaji Kumar, Hiromasa Hideshima, Norihiko Shiraishi, Hiroshi Yasui, Aldo M. Roccaro, Paul Richardson, Klaus Podar, Steven Le Gouill, Dharminder Chauhan, Kazuo Tamura, Jack Arbiser, Kenneth C. Anderson

Blood (2005) 106 (5): 1794–1800.

https://doi.org/10.1182/blood-2005-01-0346

Published: 2005

Journal Articles

Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.

Teru Hideshima, MD, PhD, Pierfrancesco Tassone, MD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Constantine Mitsiades, MD, PhD, Noopur Raje, MD, Shaji Kumar, MD, Makoto Hamasaki, MD, PhD, Hiromasa Hideshima, Nikhil C. Munshi, MD, Paul G. Richardson, MD, David Schenkein, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2351.

https://doi.org/10.1182/blood.V104.11.2351.2351

Published: 2004

Journal Articles

Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-β Inhibitors.

Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Noopur Raje, MD, Shaji Kumar, MD, Klaus Podar, MD, PhD, Constantine Mitsiades, MD, PhD, Hiromasa Hideshima, Lynn Bonham, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Jack W. Singer, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2411.

https://doi.org/10.1182/blood.V104.11.2411.2411

Published: 2004

Journal Articles

Honokiol Overcomes Conventional Drug Resistance in Human Multiple Myeloma.

Kenji Ishitsuka, M.D., Ph.D, Teru Hideshima, M.D., Ph.D, Makoto Hamasaki, M.D., Ph.D, Raje Noopur, M.D., Ph.D, Kumar Shaji, M.D., Ph.D, Hiromasa Hideshima, Norihiko Shiraishi, Ph.D, Paul Richardson, M.D., Ph.D, Nikhil C. Munshi, M.D., Ph.D, Dharminder Chauhan, Ph.D, Jack Arbiser, M.D., Ph.D, Kenneth C. Anderson, M.D., Ph.D

Blood (2004) 104 (11): 1488.

https://doi.org/10.1182/blood.V104.11.1488.1488

Published: 2004

Journal Articles

P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.

Teru Hideshima, MD, PhD, Klaus Podar, MD, PhD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Constantine Mitsiades, MD, PhD, Yu-Tzu Tai, PhD, Makoto Hamasaki, MD, PhD, Noopur Raje, MD, Hiromasa Hideshima, George Schreiner, MD, PhD, Aaron Nguyen, PhD, Tony Navas, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Linda S. Higgins, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 3348.

https://doi.org/10.1182/blood.V104.11.3348.3348

Published: 2004

NARROW

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.

Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-β Inhibitors.

Honokiol Overcomes Conventional Drug Resistance in Human Multiple Myeloma.

P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.

Email alerts

ASH Publications

American Society of Hematology

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.

Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-β Inhibitors.

Honokiol Overcomes Conventional Drug Resistance in Human Multiple Myeloma.

P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only